Pure Global
NCT03801590

Crosslinking in Infectious Keratitis

Safety and Efficacy Of Corneal Collagen Crosslinking (CXL) In Infectious Keratitis
Assiut University·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Infectious Keratitis
Drug/Device/Intervention
Crosslinking with Riboflavin and UV-A
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Assiut University
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2021
End date
Jan 01, 2023
Enrollment
20 participants
Primary outcome

Determine the duration for corneal ulcer healing

Summary

Microbial keratitis is an infection of the cornea that is associated with risk of permanent
 visual impairment.
 
 It can be caused by bacteria, virus, fungus, protozoa and parasites. The common risk factors
 for infectious keratitis include ocular trauma, contact lens wear, recent ocular surgery,
 preexisting ocular surface disease, dry eyes, lid deformity, corneal sensation impairment,
 chronic use of topical steroids and systemic immunosuppression .

ICD-10 classifications
KeratitisKeratitis, unspecifiedOther keratitisHerpesviral keratitis and keratoconjunctivitisKeratitis and keratoconjunctivitis in other infectious and parasitic diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03801590
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT03801590 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Infectious Keratitis. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.